All News

30 September 2010

Peregrine and Affitech to Amend License Agreements to Expedite Development of Novel Fully Human Anti-VEGF Antibody AT001/R84Antibodies

30 September 2010

AVEO Pharmaceuticals Regains Worldwide Rights to Develop and Commercialize Anti-HGF Antibody Candidate AV-299Antibodies

29 September 2010

XOMA 052 Phase 2a Trial Enrollment CompletedAntibodies

28 September 2010

Morphotek, Inc. Announces Selection of a Therapeutic Monoclonal Antibody for Clinical Development under Terms of Collaboration with Human Genome SciencesAntibodies

27 September 2010

Seattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and Refractory Hodgkin LymphomaAntibodies

27 September 2010

Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI Label in Treatment of Rheumatoid ArthritisAntibodies

24 September 2010

MabThera receives CHMP positive opinion in Europe for first line maintenance treatment of follicular lymphoma, a common type of blood cancerAntibodies

24 September 2010

Roche to provide EU regulatory update on Avastin in metastatic breast cancerAntibodies

23 September 2010

Tolerx Presents Research at European Diabetes Meeting and Enrolls First Patient in Europe in the DEFEND-2 Phase 3 Clinical Study in Type 1 DiabetesAntibodies

21 September 2010

ImmunoGen, Inc. Announces Start of SAR566658 Clinical TestingAntibodies

21 September 2010

Roche provides results on Avastin in adjuvant colon cancerAntibodies

20 September 2010

Celldex Therapeutics Announces Initiation of Randomized Phase 2b Clinical Trial of CDX-011 in Advanced Breast CancerAntibodies

20 September 2010

Ablynx Reports Positive Phase I Data for its Anti-Rankl NanobodyAntibodies

20 September 2010

NasVax Initiates Phase 2a Clinical Trial for Oral Anti-CD3 ImmunotherapyAntibodies

20 September 2010

Micromet Initiates Phase 2 Trial of Blinatumomab in Adult Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaAntibodies

20 September 2010

Epistem to Present Data from Their Model of Crohn’s Disease Colitis at the Inflammation Research Association ConferenceAntibodies

20 September 2010

Genentech Provides Update on Avastin for Advanced Breast CancerAntibodies

16 September 2010

GlaxoSmithKline and Genmab Refocus Development Program for Ofatumumab in Autoimmune IndicationsAntibodies

14 September 2010

Biotie completes Phase I with VAP-1 antibody – BTT-1023 continues to demonstrate favourable safety profileAntibodies

14 September 2010

Genmab and Seattle Genetics Enter into Antibody-Drug Conjugate Research CollaborationAntibodies

14 September 2010

TenX Biopharma Publishes Data on Phase II Peripheral T-Cell Lymphoma TrialAntibodies

13 September 2010

Progenics’ Humanized Monoclonal Antibodies Significantly Improve Survival in an Animal Model of C. difficile-associated DiseaseAntibodies

13 September 2010

Excelimmune Presents Preclinical Data at ICAAC Demonstrating that Human Recombinant Polyclonal Antibody Therapy Provides Protection Against MRSAAntibodies

13 September 2010

Seattle Genetics Announces Phase IIb Trial of Lintuzumab (SGN-33) in Patients with Acute Myeloid Leukemia (AML) Did Not Meet Primary EndpointAntibodies

9 September 2010

Phase 3 Trial of Sanofi-Aventis (France) (SASY.PA) And Regeneron Pharmaceuticals, Inc. (REGN)’s Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring CommitteeAntibodies

9 September 2010

Acceleron Pharma Announces Joint Development and Commercialization Agreement with Shire plc on Novel Muscle Therapeutics for Orphan Diseases in Deal Worth up to $498 MillionAntibodies

8 September 2010

GSK and Genmab Announce Start of Ofatumumab Phase III Combination Study in Non-Hodgkin’s LymphomaAntibodies

8 September 2010

PROLIA(TM) (denosumab) APPROVED BY HEALTH CANADA FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTUREAntibodies

8 September 2010

Anti-Angiogenic Anti-Cancer Agent Avastin Condition for Approval (All Patients Surveillance) Removed in JapanAntibodies

8 September 2010

Emergent BioSolutions Announces Commencement of Phase I Clinical Trial for Monoclonal Antibody to Treat Inhalational AnthraxAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

EpCAM-Targeted Antibodies Pipeline Review

Aflibercept (Eylea) Biosimilars Pipeline Review

Mesothelin-Targeted Immunotherapy Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

c-Met-Targeted Antibody Therapy Pipeline Review

Report Package: Bispecific Antibodies

Nectin-4-Targeted Immunotherapy Pipeline Review

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

CD38-Targeted Antibody & Cell Therapy Pipeline Review